S

Sanford Health | Clinical Research Department

Research site
(Unclaimed)
Location
1305 W. 18th Street, Sioux Falls, South Dakota, United States of America

Site insights

Top conditions

Top treatments

Macitentan
Milademetan
Cenicriviroc
Alcohol
Osimertinib
Morphine
Ompenaclid
Methadone
Cyclosporine
CB-839

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 55 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling
Myelofibrosis
Drug: Imetelstat
Drug: Best Available Therapy (BAT)

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Drug: ACR-368
Diagnostic Test: OncoSignature

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Amivantamab

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Enrolling
Solid Tumor
APC Gene Mutation
Drug: REC-4881

This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e.,...

Enrolling
Colorectal Carcinoma
KRAS Mutation-Related Tumors
Drug: ompenaclid
Drug: FOLFOX regimen

This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Tepotinib
Drug: Osimertinib

The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibi...

Enrolling
Treatment of Patients Suffering From Overactive Bladder (OAB)
Device: RENOVA iStim™ System

This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors,...

Enrolling
GI Cancer
Solid Tumors
Drug: Pembrolizumab
Drug: CGX1321

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Drug: Tadalafil 40 mg
Drug: Placebo FDC

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with typ...

Enrolling
Type 1 Diabetes
Device: Subject's Current Diabetes Therapy
Device: 670G and 770G Insulin Pump

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...

Active, not recruiting
Solid Tumor
Locally Advanced Solid Tumor
Drug: Niraparib

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting
Solid Tumor
Malignant Neoplasm
Drug: nab-sirolimus

: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherape...

Active, not recruiting
COVID-19
SARS-CoV2
Biological: SAB-185
Other: Normal Saline
Locations recently updated

Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...

Enrolling
Prostate Cancer
Drug: Abiraterone
Drug: Enzalutamide

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus...

Active, not recruiting
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Biological: IMNN-001
Drug: Carboplatin

This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/ref...

Enrolling
Solid Tumor
Refractory Tumor
Biological: STI-6643

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple asce...

Active, not recruiting
Primary Biliary Cholangitis
Drug: CNP-104
Drug: Placebo

Trial sponsors

I
J
National Cancer Institute (NCI) logo
A
A
Abbott logo
A
Actelion Pharmaceuticals logo
Amgen logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems